Sep 2, 2026, 6:30 AM EDT · 4 weeks ago Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
Sep 1, 2026, 6:30 AM EDT · 4 weeks ago Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
Aug 11, 2026, 6:30 AM EDT · 7 weeks ago Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jun 10, 2026, 6:30 AM EDT · 3 months ago Immunic to Participate in Investor, Industry and Scientific Conferences in June
May 28, 2026, 6:30 AM EDT · 4 months ago Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
2026-05-27T10:45:55.000Z · 4 months ago Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed
May 27, 2026, 6:30 AM EDT · 4 months ago Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
May 19, 2026, 6:30 AM EDT · 4 months ago Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
May 13, 2026, 6:30 AM EDT · 4 months ago Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Apr 30, 2026, 6:30 AM EDT · 5 months ago Immunic to Participate in Investor and Medical Conferences in May
2026-04-30T10:14:29.000Z · 5 months ago Immunic price target adjusted to $22 from $5 at H.C. Wainwright
2026-04-28T11:19:28.000Z · 5 months ago Immunic CMO Andreas Muehler to depart, Michael Panzara to succeed
Apr 28, 2026, 6:30 AM EDT · 5 months ago Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.
Apr 9, 2026, 6:30 AM EDT · 5 months ago Immunic to Participate in Scientific and Medical Conferences in April
Apr 1, 2026, 6:30 AM EDT · 6 months ago Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Mar 31, 2026, 6:30 AM EDT · 6 months ago Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Mar 10, 2026, 6:30 AM EDT · 6 months ago Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Feb 26, 2026, 6:30 AM EST · 7 months ago Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Feb 17, 2026, 4:05 PM EST · 7 months ago Immunic Announces Closing of Oversubscribed Private Placement Financing
Feb 13, 2026, 6:30 AM EST · 7 months ago Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Feb 4, 2026, 6:30 AM EST · 8 months ago Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Jan 7, 2026, 6:30 AM EST · 8 months ago Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Nov 26, 2025, 6:30 AM EST · 10 months ago Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Nov 13, 2025, 6:30 AM EST · 10 months ago Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 29, 2025, 6:30 AM EDT · 11 months ago Immunic to Participate in Industry and Investor Conferences in November
Oct 1, 2025, 6:30 AM EDT · 1 year ago Immunic to Participate in Scientific and Investor Conferences in October
Sep 25, 2025, 6:30 AM EDT · 1 year ago Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
Sep 9, 2025, 6:30 AM EDT · 1 year ago Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
Sep 4, 2025, 6:30 AM EDT · 1 year ago Immunic to Participate in Investor and Scientific Conferences in September
Aug 7, 2025, 6:30 AM EDT · 1 year ago Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jun 24, 2025, 6:30 AM EDT · 1 year ago Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Jun 5, 2025, 6:30 AM EDT · 1 year ago Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Jun 3, 2025, 4:01 PM EDT · 1 year ago Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
Jun 2, 2025, 6:30 AM EDT · 1 year ago Immunic to Participate in Investor, Scientific and Industry Conferences in June
May 29, 2025, 7:05 AM EDT · 1 year ago Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
May 2, 2025, 6:30 AM EDT · 1 year ago Immunic to Participate in Scientific and Industry Conferences in May
Apr 30, 2025, 7:30 AM EDT · 1 year ago Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Apr 10, 2025, 1:00 PM EDT · 1 year ago Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Apr 9, 2025, 8:10 AM EDT · 1 year ago Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Apr 1, 2025, 6:30 AM EDT · 1 year ago Immunic, Inc. to Participate in Scientific and Industry Conferences in April
Mar 3, 2025, 6:30 AM EST · 1 year ago Immunic to Participate in Scientific and Investor Conferences in March
Feb 26, 2025, 6:30 AM EST · 1 year ago Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Feb 20, 2025, 7:30 AM EST · 1 year ago Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Feb 4, 2025, 6:30 AM EST · 1 year ago Immunic to Participate in Investor and Scientific Conferences in February
Jan 7, 2025, 6:30 AM EST · 1 year ago Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Nov 26, 2024, 6:30 AM EST · 1 year ago Immunic, Inc. to Participate in Investor Conference in December
Nov 13, 2024, 6:30 AM EST · 1 year ago Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Nov 7, 2024, 6:30 AM EST · 1 year ago Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update